Amicus Therapeutics, Inc. (FOLD) News
Filter FOLD News Items
FOLD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FOLD News Highlights
- FOLD's 30 day story count now stands at 6.
- Over the past 22 days, the trend for FOLD's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- DRUG are the most mentioned tickers in articles about FOLD.
Latest FOLD News From Around the Web
Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.
Amicus (FOLD) Gets FDA Approval for Pompe Disease DrugAmicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease. |
UPDATE 1-US FDA approves Amicus Therapeutics' muscle disorder treatmentAmicus Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a muscle disorder called Pompe disease. The health regulator last October extended its review for a second time following delays in inspections caused by pandemic-related travel restrictions. The therapy is indicated for use in adults living with late-onset Pompe disease and those without an improvement on their current enzyme replacement therapy, the company said. |
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe DiseasePombiliti + Opfolda Logo Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (migl |
Amicus Therapeutics Stock Reaches 80+ Relative Strength BenchmarkAmicus Therapeutics just cleared that benchmark with an upgrade from 77 to 82. Amicus Therapeutics is trying to complete a consolidation with a 14.10 buy point. Amicus Therapeutics earns the No. 39 rank among its peers in the Medical-Biomed/Biotech industry group. |
Zacks.com featured highlights include Amicus Therapeutics, Genius Sports and ViadAmicus Therapeutics, Genius Sports and Viad are part of the Zacks Screen of the Week article. |
Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Monday, September 11, 2023, at 11:20 a.m. E.T.Cantor Global Healthcare Conference 2023 in New York, NY on Wednesday, September 27, 2023, at 1:15 p.m. E.T. A live audio webcast of each presentation can also be acces |
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel. Oral Presentation: Pompe Disease: Abstract Title: Switching treatment from alglucosidase alfa to cipaglucosidase alfa plus miglustat positively affects m |
Amicus Therapeutics Appoints Simon Harford as Chief Financial OfficerDaphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most |
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United KingdomPombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation PHILADELPHIA and MARLOW, United Kingdom, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Medicines and |